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22Objective: The objective is to test the concept of ‘‘pay for performance’’ for patients with non–small cell lung
cancer.
Methods: We constructed 53 benchmark performance standards (10 labeled ‘‘critical’’) and prospectively as-
sessed the effect of adherence to these standards on morbidity and mortality for patients undergoing resection
of non–small cell lung cancer.
Results: Between January 1, 2007, and December 31, 2009, 778 patients with non–small cell lung cancer un-
derwent thoracotomy by 1 surgeon. Ninety-seven percent of patients received all 26 of the ‘‘day of surgery’’ and
‘‘intraoperative’’ benchmarks, and thosewere the easiest to deliver. The 469 patients who had all 53 benchmarks
delivered, compared with the 309 who did not, had a lower mortality (2.0% vs 2.3%) and morbidity (16% vs
44%; P<.001). The 693 patients who received all 10 ‘‘critical’’ benchmarks, compared with the 85 who did not,
had a lower mortality (1.9% vs 4.7%) and morbidity (25% vs 41%; P ¼ .003). Low household income and
fewer than 2 people in the household were predictors of overall morbidity on univariate analysis.
Conclusions: Most benchmarks, especially ‘‘day of surgery’’ and ‘‘intraoperative’’ ones, can be delivered in
more than 97% of patients. The delivery of benchmarks reduces perioperative morbidity but not mortality.
Socioeconomic factors are predictors of overall morbidity. Operative mortality is related to the ‘‘quality of
the patient’’ and the ‘‘quality of the health care provider.’’ (J Thorac Cardiovasc Surg 2011;141:22-33)Earn CME credits at
http://cme.ctsnetjournals.org
In 2001, the Institute of Medicine recommended that health
plans adopt a pay for performance concept.1,2 The theory
was that if physicians were rewarded for the delivery of
high-quality care instead of receiving payment based on
the quantity of care, quality would improve and patient out-
comes would improve. Although the concept is sound, the
data supporting it are mixed. We are all aware of patients
who receive outstanding care but have bad outcomes. In ad-
dition, several studies have shown little to no effect of the
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The Journal of Thoracic and Cardiovascular Surgestudies tested the concept of cancer screening programs in
Medicaid patients, the second was patient outcomes after
myocardial infarction, and the third evaluated enhancing
mammography in primary care. However, 3 other studies
did show improve outcomes when pay for performance
was adopted.6-8 These studies concerned diabetes
management, mammography, and the reduction of lipid
levels. The concept has also been been studied in patients
with non–small cell lung cancer (NSCLC), and although
none of those or our benchmarks (or quality metrics) have
been validated, we have all chosen similar ones.9,10 In this
study we evaluated the ‘‘pay for performance’’ concept
when applied to the surgical care of patients with NSCLC
who undergo thoracotomy and pulmonary resection. We
identified benchmarks and evaluated our ability to deliver
them. We divided the benchmarks into 4 categories
that we believed were important to the care of patients
with NSCLC: preoperative benchmarks, day of surgery,
intraoperative, and postoperative benchmarks The goal of
this study was to assess our ability to deliver these
benchmarks and then to analyze how the delivery affected
patient outcomes, specifically operative mortality, major
morbidity, and overall morbidity.
METHODS
In December 2006 we decided to try to further improve the overall care
that we provided for patients with NSCLC. The goal was to provide the ab-
solute best care possible, orwhat we labeled ‘‘optimal care,’’ for patientswho
called our office and then underwent rib-sparing, intercostal nerve-sparing
thoracotomy.11-13 We assessed all aspects of our care that we could. We
assessed our ability to get patients into the preoperative clinic quickly, tory c January 2011
Abbreviations and Acronyms
ICU ¼ intensive care unit
NSCLC ¼ non–small cell lung cancer
PQRI ¼ Physician’s Quality Reporting
Initiative
STS ¼ The Society of Thoracic Surgeons
UAB ¼ University of Alabama at Birmingham
VATS ¼ video-assisted thoracic surgery
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Preoperative staging tests were performed as previously described.14,15
We identified all of the aspects of patient care that seemed important and
evaluated those along with relevant ones previously sited, such as in the
Physician’s Quality Reporting Initiative (PQRI).16 We labeled these
‘‘benchmarks.’’ The 53 benchmarks selected for this study are listed in
Table 1. Our ability to deliver each benchmark for each patient was re-
corded. We then evaluated the benchmark’s relationship to outcome.
Benchmarks were subclassified in various ways: (1) the time that the
benchmark was delivered during the patient’s care: ‘‘preoperatively,’’
‘‘day of surgery,’’ ‘‘intraoperatively,’’ or postoperatively’’; (2) ‘‘critical’’
(defined as specific aspects of care that were vital to ensuring a good out-
come) and ‘‘noncritical’’ (all others); (3) impact factor (a subjective score
given to each benchmark from 1–5, with 1 being least critical and 5 being
most critical to patient outcomes). All critical benchmarks received an im-
pact factor of 5. A fourth category of benchmarks was based on the aspect
of care that they addressed. They were called either ‘‘quality of care’’
benchmarks or ‘‘patient satisfaction’’ benchmarks.
In addition, we created a score for each patient that we called a weighted
score. Theweighted scorewas calculated by multiplying the quality of care
benchmarks only by the impact factor and then adding all of the scores for
each benchmark for 1 patient. ‘‘Patient and family’’ satisfaction bench-
marks were eliminated from this calculation. In addition, we eliminated
benchmarks that all patients were not eligible to receive. For example,
one of the benchmarks was for smoking cessation; however, if a patient
did not smoke, he or she was not eligible to receive this benchmark. There-
fore, in the weighted score calculation this benchmark was eliminated.
Primary outcomes were analyzed for 3 distinct outcomes: operativemor-
tality,majormorbidity, and overallmortality.Morbiditywas defined accord-
ing to The Society of Thoracic Surgeons (STS) database definitions.17 We
subdivided morbidity into major (adult respiratory distress syndrome, pul-
monary emboli, reintubation, myocardial infarction, stroke, empyema, gas-
trointestinal complication requiring surgery, transfer to the intensive care
unit [ICU] for any reason, and acute renal failure) or minor (all of the re-
maining morbidities listed in the STS thoracic database version 2.081). Op-
erative mortality was defined as death within 30 days of operation or before
discharge. The Institutional Review Board of the University of Alabama at
Birmingham (UAB) approved this study and the prospective database used
to record this information. Individual patient consentwas obtained for inclu-
sion in our prospective database but waived for this particular study.
In the clinic, patients were asked to fill out a demographic survey (as
shown in Appendix 1) that obtained a wide variety of socioeconomic infor-
mation. These included questions about their highest level of education and
degree obtained, their median income over the past 20 years, and the num-
ber of dependents living in their home. This information was not shown to
the surgical team.
Data were initially recorded in an Excel database (Microsoft Corp,
Redmond, Wash) and analyzed with SAS version 9.1 (SAS Inc, Cary, NC).
Categorical data are presented as percentages and continuous variables as
medians. Fisher’s exact test or the Pearson c2 test was used to assess categor-
ical data and the Wilcoxon test to evaluate continuous variables. UnivariateThe Journal of Thoracic and Cand stepwise Wald multivariate logistic regression analyses of risk factors
for operative mortality, major morbidity, and overall morbidity were per-
formed by calculating an adjusted odds ratio with 95% confidence interval.
The following analyses were performed: (1) the types and percentage of
benchmarks that were delivered, (2) the outcomes of patients who had all of
the benchmarks delivered compared with those who did not, (3) the out-
comes of patients who had all 10 critical benchmarks delivered compared
with those that did not, (4) the outcomes of patients based on their weighted
score, (5) a univariate analysis of outcomes based on known STS patient
risk factors (age, gender, Zubrod score, American Society of Anesthesiol-
ogists class, diabetes mellitus, renal dysfunction, preoperative therapy, pul-
monary function test results, and smoking history) and socioeconomic
variables collected in our clinic, and (6) a multivariate analysis using
variables that had a P value of .08 or lower in the univariate analysis.RESULTS
Between January 1, 2007, and December 31, 2009, 778
patients with NSCLC underwent elective rib-sparing,
nerve-sparing thoracotomy with intent to cure by 1 general
thoracic surgeon. The patient characteristics are shown in
Table 2. The causes of operative mortality, major morbidity,
and overall morbidity are shown in Table 3. The first anal-
ysis performed was the types and percent of benchmarks
that were delivered. Table 1 shows the individual bench-
marks and the percent of patients that achieved each bench-
mark. Only 469 (60%) patients had all of the benchmarks
delivered. As shown in Table 1, the most frequently deliv-
ered benchmarks were those in the ‘‘day of surgery’’ cate-
gory (mean, 99.8%). Second most commonly delivered
were the ‘‘intraoperative’’ benchmarks (mean, 97%). The
individual benchmark least likely to be delivered was
benchmark 14 (cardiopulmonary rehabilitation program be-
fore surgery for selected patients), which was delivered in
only 42% of patients. However, only 222 patients were
eligible for this benchmark, as shown in Table 1.
The second analysis was to compare the mortality and
morbidity of the 469 patients who had all of the benchmarks
delivered compared with those who did not. There was no
significant difference in the operative mortality between
patients who did and did not achieve all of the benchmarks
(9 patients, 2.0%, versus 8 patients, 2.6%, respectively;
P¼ .532). Additionally, there was no significant differences
in the major morbidity in patients who did and did not
achieve all benchmarks (9.2%) when compared with those
who did not receive all of the benchmarks (9.4%; P¼ 1.0).
However, when the overall morbidity was analyzed, the 469
patients who had all 53 benchmarks delivered had a lower
overall morbidity (16%) than did the 309 patients who
did not get all the benchmarks delivered (44%; P<.001).
The third analysis performed was patient outcomes, com-
paring the 693 (89%) patients who had all 10 critical bench-
mark delivered and the 85 (11%) patients who did not. The
operative mortality was once again no different between the
2 groups (13/693, 1.9%, vs 4/85, 4.7%, respectively;
P ¼ .196). However, patients who had all of the critical
benchmarks delivered had significantly less majorardiovascular Surgery c Volume 141, Number 1 23
TABLE 1. List of benchmarks and their classification and the number of patients who received them
Benchmark Timing Critical
Impact
factor Classification
Patients eligible for
benchmark (%)
Eligible patients who
achieved benchmark (%)
Preoperative
1 See patient in clinic  2 weeks of patient
calling or referral physician calling for
appointment
Pre No 1 Satisfaction 100% 100%
2 Integrated PET/CT performed  30 days
of surgery
Pre No 4 Quality 100% 83%
3 Computed tomography scan w/contrast
(5-mm columinated cuts) performed
 30 days of surgery
Pre No 3 Quality 85%(1) 100%
4 Have board-certified general and
cardiothoracic surgeon who performs
only general thoracic surgery clinically
stage and evaluate patient*
Pre Yes 5 Quality 100% 100%
5 Clinical TNM stage determined and recorded
prior to surgery
Pre Yes 5 Quality 100% 100%
6 Surgery and/or definitive staging procedures
offered  3 weeks of seeing the surgeon
Pre No 3 Quality 93%(2) 100%
7 If tumor>4 cm, central, and/or has
a maxSUVof 9 or greater, mediastinal
staging procedures such as EUS–FNA
and/or EBUS performed with rapid on site
cytology and/or mediastinoscopy
performed
Pre No 4 Quality 37%(3) 100%
8 If maxSUVof lymph node is>50% of
primary tumor, biopsy of that node is
performed (unless it is an isolated #5 or
#6 lymph node in selected patients)
Pre No 3 Quality 40%(3) 100%
9 Anesthesia to evaluate patient on same day of
clinic appointment
Pre No 1 Satisfaction 92%(4) 68%
10 Stress test performed for patients with
a smoking history of  20 pack-years or
have history of coronary artery disease
Pre No 4 Quality 72%(5) 97%
11 Cardiology clearance if patient has abnormal
stress test
Pre No 3 Quality 16%(6) 100%
12 Full set of pulmonary function tests
including FEV1%, DLCO%, and
DLCO/VA%  30 days of surgery*
Pre No 3 Quality 100% 89%
13 Smoking cessation classes and/or
prescription and pamphlets given
 2 weeks before surgery
Pre No 5 Quality 57%(7) 88%
14 Cardiopulmonary rehabilitation program for
1 month before surgery in selected patients
Pre Yes 5 Quality 26%(8) 42%
Day of surgery
15 Admitted the day of surgery DOS No 1 Satisfaction 100% 98%
16 Have updated history and physical
examination documented before surgery
DOS No 2 Quality 100% 100%
17 Administer a dose of antibiotics before skin
incision and write postop order to stop
antibiotics after first dose
DOS No 2 Quality 100% 100%
18 Time out to ensure the correct procedure is
carried out
DOS No 2 Quality 100% 100%
19 Board-certified cardiothoracic
anesthesiologist present during induction*
DOS Yes 5 Quality 100% 100%
20 Perform bronchoscopy before skin incision DOS No 3 Quality 100% 100%
(Continued)
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TABLE 1. Continued
Benchmark Timing Critical
Impact
factor Classification
Patients eligible for
benchmark (%)
Eligible patients who
achieved benchmark (%)
21 During mediastinoscopy, at least 2 lymph
node stations biopsied and frozen
pathology provided
DOS No 4 Quality 52%(9) 100%
22 Patients who are N2 positive have their care
discussed at multispecialty cancer
conference OR Patients who are N2
negative who are not to have neo-adjuvant
therapy have primary tumor resected
within 1 week of mediastinoscopy and
within 2 weeks of EBUS and EUS–FNA
DOS No 4 Quality 100% 100%
Intraoperative
23 Patients who are  70 years of age get
epidural,>70 years get pain pump
Intra No 3 Quality 100% 94%
24 Intraoperative injection of subcutaneous
heparin
Intra No 3 Quality 100% 98%
25 Attending surgeon makes skin incision, is
present for opening, for dissection of
and ligation of all major vessels, and for
lymph node removal. Also present for
chest closure up to the skin*
Intra Yes 5 Quality 100% 100%
26 Family called when incision is made Intra No 1 Satisfaction 90%(10) 98%
27 Had a rib-sparing, muscle-sparing, nerve-
sparing thoracotomy
Intra Yes 5 Quality 100% 100%
28 Palpation of all nonresected lobes of the
ipsilateral lung
Intra No 3 Quality 100% 100%
29 Complete thoracic lymphadenectomy
performed for patients with lung cancer on
the right side; resection of all of the 2R,
4R, 7, 8, and 9 and on the left side
resection of the 4L, 5, 6, 7, 8L, and 9L and
removal of all appropriate N1 nodes
Intra No 4 Quality 100% 100%
30 Lobectomy performed for all patients except
those with bronchoalveolar carcinoma,
those with a primary tumor>2 cm, or
selected patients with low DLCO% or
FEV1%
Intra No 4 Quality 100% 100%
31 Negative bronchial margin, verified in the
operating room by frozen section
Intra No 4 Quality 100% 100%
32 Negative stapled margins verified in the
operative room by frozen section, i.e.,
an complete resection
Intra No 4 Quality 100% 100%
33 One chest tube used for lobectomy, unless
clinically scenario documented why 2
were used
Intra No 3 Quality 100% 83%
34 Chest tube placed to wall suction on the day
of surgery, to water seal next morning
Intra No 3 Quality 100% 94%
35 Pulmonary resection performed<1 hour
40 minutes, skin to skin in patients
who have not had neoadjuvant
chemotherapy, radiation, or prior
ipsilateral thoracotomy; otherwise
within 2.5 hours*
Intra Yes 5 Quality 100% 87%
36 Skin incision time before 14:00 Intra No 2 Satisfaction 95% 95%
37 Blood loss<125 mL during operation* Intra Yes 5 Quality 100% 96%
(Continued)
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TABLE 1. Continued
Benchmark Timing Critical
Impact
factor Classification
Patients eligible for
benchmark (%)
Eligible patients who
achieved benchmark (%)
38 No packed red blood cell transfusion
given in the operating room*
Intra Yes 5 Quality 99%(11) 98%
39 Needle and sponge count before leaving
the operating room
Intra No 2 Quality 100% 100%
40 Chest radiography performed in recovery
room
Intra No 2 Quality 100% 100%
Postoperative
41 Admitted directly to a specialized floor
with nurses experienced in caring for
patients who have had a pulmonary
resection (avoid ICU admission)*
Post Yes 5 Quality 100% 96%
42 Pain service (anesthesia) involved in patients
postop care in patients with epidural
Post No 3 Quality 100% 99%
43 Daily subcutaneous heparin injections
ordered and compression stockings worn
at all times
Post No 3 Quality 100% 96%
44 Appropriate consults ordered: social work,
nutrition, anesthesia, respiratory, physical
therapy
Post No 3 Satisfaction 100% 87%
45 Respiratory therapists at bedside at least 2
times per day
Post No 5 Quality 100% 100%
46 Chest radiograph ordered only as needed
and chest posteroanterior/lateral film
ordered after last chest tube is removed
Post No 2 Quality 100% 100%
47 Discharge by POD 4, unless social issues
delay discharge*
Post Yes 5 Quality 100% 88%
48 Cardiology consult ordered if atrial
arrhythmia lasts>24 hours, or elevated
cardiac enzymes
Post No 3 Quality 15% 100%
49 Follow-up appointment within 3 weeks
postop
Post No 1 Satisfaction 100% 87%
50 Prescription for pain medication given
before discharge
Post No 2 Satisfaction 100% 100%
51 Patient sent home with a telephone number
to be able to contact a thoracic team
member 24 hours a day, 7 days a week
Post No 1 Satisfaction 100% 100%
52 Pathology report available by POD 3 or
before discharge. Otherwise patient
instructed to call office for pathology
results after discharge
Post No 1 Satisfaction 100% 80%
53 An appointment with oncologist<4 weeks
if postop adjuvant treatment indicated
Post No 2 Quality 52%(12) 89%
Reasons that some patients were not eligible for benchmarks (<100%): (1) Creatinine too high for some patients to be eligible for computed tomography scan. (2) Some patients
not able to go right to surgery. Patient’s whose schedules did not allow or if they were not physically fit, were not eligible. (3) Some patients had smaller tumor or lower maxSUV.
(4) Some patients arrived to clinic too late and thus could not make it to anesthesia clinic before closing time. (5) Some patients were nonsmokers or smoked less than this amount.
(6) Some patients had normal stress test, no significant history of heart disease, or no history of smoking. (7) Some patients were nonsmokers or had already stopped smoking. (8)
Patients with normal stress test were not eligible. (9) Some patients did not have a mediastinoscopy. (10) Operating room staff forgot to call or family unavailable/unable to be
located. (11) Patients who were Jehovah’s Witnesses or refused blood products were not eligible. (12) Some patients did not require additional treatment. PET, Positron emission
tomography; CT, computed tomography; maxSUV, maximum standardized uptake value; EUS, endoscopic ultrasound; FNA, fine needle aspiration; EBUS, endobronchial ultra-
sound; FEV1%, percent forced expiratory volume in 1 second; VA, alveolar volume; DLCO%, percent diffusion lung capacity for carbon monoxide; ICU, intensive care unit;
POD, postoperative day; DOS, day of surgery. *Critical benchmarks.
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morbidity (25% compared with 41%; P<.003).
The fourth analysis compared theweighted scores for each
patient. The weighted score was calculated by using only the26 The Journal of Thoracic and Cardiovascular Surge‘‘quality of care’’ benchmarks and benchmarks that all pa-
tientswere eligible to receive.We thenmultiplied it by the im-
pact factor for each one of these benchmarks to generate
a total weighted score for each patient. The highestry c January 2011
TABLE 2. The patient characteristics are shown below (N ¼ 778)
Age (median years) ± SD, range 67 ± 10 (19–86)
Gender
Male 388 (50%)
Female 390 (50%)
Zubrod score, median, range 1 (0–2)
ASA class, median, range 3 (2–4)
Type of pulmonary resection
Pneumonectomy 15 (2%)
Lobectomy/bilobectomy/sleeve lobectomy 499 (61%)
Sublobar resection 264 (34%)
Pulmonary function tests
FEV1% (median)  SD 78%  12
DLCO% (median)  SD 89%  14
>Twenty pack-year smoking history and current
smoker (smoked within past month)
276 (35%)
Received neoadjuvant therapy
Yes 109 (13.6%)
No 669 (86.4%)
History of coronary artery disease
Yes 171 (22%)
No 607 (78%)
History of preoperative renal dysfunction (dialysis)
Yes 53 (6.8%)
No 725 (93.2%)
Diabetes mellitus
Yes 120 (15.4%)
No 658 (84.6%)
ASA, American Society of Anesthesiologist; FEV1%, percent forced expiratory
volume in 1 second; DLCO%, percent diffusion lung capacity for carbon monoxide;
SD, standard deviation.
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102.Weighted scorewasnot associatedwithoperativemortal-
ity norwas it associatedwithmajormorbidity.However,more
patients who had overall morbidity had a significantly lower
weighted score (average score, 113) than did those patients
without any morbidity (average score, 116.7; P<.001).
Table 4 shows the results of the fifth analysis, which was
univariate factors that assessed outcomes based on known
STS risk factors and on the patient’s socioeconomic factors.
As shown in Table 4, only age, smoking status, percent
forced expiratory volume in 1 second, types of pulmonary
resection, and coronary artery disease were significantly as-
sociated with mortality on univariate analysis. When major
morbidity was analyzed, several factors were associated
with a worse outcome: patients who did not receive all of
the critical benchmarks, age, male gender, higher Zubrod
score, lower percent diffusion lung capacity for carbon
monoxide, current smoker, history of coronary artery dis-
ease, types of pulmonary resection, and residing either by
themselves or with 1 other person were significantly associ-
ated with major morbidity. When overall morbidity was
analyzed, factors that were statistically associated with
worse outcomes were age, male sex, lower percent forced
expiratory volume in 1 second, lower percent diffusionThe Journal of Thoracic and Clung capacity for carbon monoxide, current smokers, types
of pulmonary resection, those who lived alone or with only
1 other person, patient’s annual household income less than
$25,000, not having all the benchmarks or all of the critical
benchmarks delivered, and have a lower weighted score.
The results of the sixth analysis are shown in Table 5.
This is the multivariate analysis of the 3 types of outcomes.
It shows that only smoking status and history of coronary
artery disease remained significant predictors of operative
mortality. Predictors of major morbidity on multivariate
analysis were critical benchmarks, coronary artery disease,
smoking, and age. Finally, multivariate predictors of overall
morbidity were critical benchmarks, weighted score, coro-
nary artery disease, types of pulmonary resection, and
age. The odds ratio shows that coronary artery disease
was the most strongly associated factor to overall morbidity.
DISCUSSION
Reimbursement in thoracic surgery has already been al-
tered by the concept of pay for performance. Medicare
has proposed to pay 2% additional reimbursement to car-
diothoracic surgeons who document some of the 179
(soon to be 216) PQRI measures.18 Traditionally, private in-
surers follow Medicare’s lead. Thus reimbursement for
quality of care instead of quantity of care is already here
and its role is likely to expand. Our study attempts to exam-
ine the extreme of this system. This study was designed to
list many aspects of care that a patient with NSCLC who
was referred to a general thoracic surgeon and who went
on to pulmonary resection could get. It then critically eval-
uated whether these benchmarks could be delivered and
which ones were easy to deliver and which were not.
Then we analyzed how their delivery affected outcomes—
mortality, overall morbidity, and major morbidity.
One of the major findings in this study is that most of the
53 subjectively determined benchmarks could be delivered.
We divided the benchmarks into 4 categories on the basis
of the temporal aspect of care. In addition, we also divided
them into 2 larger categories: those concerned with patient
and family satisfaction and those with quality of care. Disap-
pointingly, only 60% of patients had all of their benchmarks
delivered despite our goal to make this 100% for every
patient. The most common ones that could be consistently
delivered were the ‘‘day of surgery’’ and ‘‘intraoperative’’
benchmarks. This makes sense inasmuch as these are the
ones over which the surgeon usually has the greatest control.
The ones most commonly not delivered were those that dealt
with the compliance of patients, such as to perform a cardio-
pulmonary rehabilitation program for 1 month before sur-
gery. One reason for failure is that some concerned
socioeconomic factors such as transportation, even though
rehabilitation was always offered to the center closest to their
home. Importantly, however, 89% of patients received all 10
critical benchmarks and 98% received at least 9 of the 10.ardiovascular Surgery c Volume 141, Number 1 27
TABLE 3. Morbidity and mortality (some patients had overlapping morbidities)
Major morbidity (includes causes of mortality,
indicated by*) (N ¼ 72)
Morbidity (includes all major morbidity and mortality)
(N ¼ 210)
Pulmonary Re-intubation<24 hrs postop 3 8
Acute respiratory distress syndrome (reintubated) 3 4*
Pulmonary embolism 3 3 (death in 2*) Empyema 3 3
‘‘Pneumonia’’ requiring transfer to ICU 3 4
Respiratory distress/hypoxia 3 3 (requiring return to operating
room for bronchcoscopy)
Pneumothorax requiring intervention 3 2,
Respiratory arrest 3 2 (death in 1*)
Prolonged intubation postoperatively x 2
Air leak—discharge with chest tube 3 9
Subcutaneous emphysema 3 4
Pulmonary edema 3 2
Mucous plug/atelectasis (bedside bronchcoscopy) 3 4
Cardiac Myocardial infarction 3 5 (death in 2*)
Ventricular tachycardia*
Cardiac arrest*
Cardiac arrhythmia requiring transfer to coronary care unit
Atrial fibrillation 3 68
Chest pain/elevated cardiac enzymes 3 4
Gastrointestinal Ileus/megacolon*
Ileus 3 4
Ischemic duodenum*
Ischemic colon*
Gastrointestinal bleeding*
Small bowel obstruction 3 2
Neurologic Seizure 3 2 (death in 1*)
Cerebrovascular accident 3 2*
Transient ischemic attack 3 2
Delirium 3 5
Excessive somnolence 3 2
Renal Acute renal failure 3 4
Pyelonephritis
Urinary tract infection 3 6
Urinary retention 3 12
Elevated creatinine 3 2
Other Narcotic withdrawal requiring admit to ICU*
Chylothorax 3 7
Bleeding/high output—take back to operative room for
exploration/wash out 3 2
Sudden death (noncardiac)
Transferred to ICU/made DNR 3 3
Deep vein thrombosis requiring treatment 3 2
Sepsis 3 2*
Multisystem organ failure (DNR) 3 3*
High fever of unknown origin/requiring intravenous antibiotics
Cellulitis
Nausea/vomiting (prolonged hospital stay) 3 9
Alcohol withdrawal 3 2
Transient hoarseness 3 2
Deep vein thrombosis (no treatment required)
Coagulopathy 3 2
Postoperative blood transfusion 3 2
Pain issues (delayed discharge) 3 4
ICU, Intensive care unit; DNR, do not resuscitate.
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on the basis of our experience and on some of the previ-
ous literature using quality improvement guides such as
the American College of Surgeon’s NSQIP (National Sur-
gery Quality Improvement Program) and the POSSUM
(Physiological and Operative Severity Score for the enU-
meration of Morbidity and mortality) score.19,20 Similar to
those criteria, our benchmarks are prone to subjectivity
and thus an obvious criticism of this study.21 However,
we believe that some of the benchmarks we selected,
such as the delivery of an operation in under 1.5 hours
and requiring no blood transfusion, are probably better
markers for ‘‘quality care’’ than those currently selected
by Medicare (ie, stopping antibiotics after postoperative
day 1 or ensuring that antibiotics are given before skin
incision).28 The Journal of Thoracic and Cardiovascular SurgeAnother important finding in this study is that the deliv-
ery of benchmarks, even when critical benchmarks were
considered, had no statistically significant impact on opera-
tive mortality. However, there was a trend toward mortality
reduction. This probably is because, as Cassivi and col-
leagues9 wrote, ‘‘operative mortality, although easily defin-
able, is difficult to use as a measure of quality of care as it is,
fortunately, an uncommon event for most [pulmonary resec-
tions] and therefore underpowered.’’ However, we found
that the 693 patients who had delivery of all 10 critical
benchmarks had significantly lower postoperative major
morbidity. This finding, though, may be in part due to the
fact that some of the critical benchmarks may be nothing
more than surrogate markers of not having had a complica-
tion. For example, benchmark 41 is ‘‘avoid going to the
ICU.’’ and it would not be achieved in a patient who isry c January 2011
TABLE 4. These variables were entered into a univariate analysis to determine association with postoperative mortality, major morbidity, and
overall morbidity
Mortality P value Major morbidity P value Overall morbidity P value
(N ¼ 17) (N ¼ 72) (N ¼ 210)
Achieved all benchmarks
Yes, N ¼ 469 9 (2.0%) .532 43 (9.2%) 1.00 75 (16%) <.001
No, N ¼ 309 8 (2.6%) 29 (9.4%) 135 (44%)
Achieved all critical benchmarks
Yes, N ¼ 693 13 (1.9%) .196 58 (8%) .015 175 (25%) .003
No, N ¼ 85 4 (4.7%) 14 (16%) 35 (41%)
Weighted score (median 117)
<117, N ¼ 389 11 (2.8%) .353 43 (11%) .08 162 (42%) <.001
 117, N ¼ 389 6 (1.5%) 29 (7.5%) 48 (12%)
Age (median age 67 y)
<67, N ¼ 389 13 (3.3%) .044 49 (12.6%) <.001 143 (37%) .001
 67, N ¼ 389 4 (1.0%) 23 (6%) 67 (17.2%)
Gender
Male, N ¼ 388 11 (2.8%) .232 46 (11.8%) .013 121 (58%) .018
Female, N ¼ 390 6 (1.5%) 26 (6.7%) 89 (42%)
Zubrod score
1. N, ¼ 597 12 (2.0%) .563 63 (11%) .027 157 (26%) .445
2.2, N ¼ 181 5 (2.7%) 9 (4.9%) 53 (29%)
FEV1% (78% median)
<8%, N ¼ 389 13 (3.3%) .047 43 (10.3%) .083 161 (41%) <.001
78%, N ¼ 389 4 (1.0%) 32 (8.2%) 49 (13%)
DLCO% (89% median)
<89%, N ¼ 389 12 (3%) .059 55 (14%) <.001 72 (18.5%) <.001
89%, N ¼ 389 5 (1.2%) 17 (4.4%) 138 (35%)
>Twenty pack-year smoking history AND
current smoker, N ¼ 276
14 (5.0%) <0.001 41 (14.9%) <0.001 95 (45%) <0.001
Coronary artery disease
Yes, N ¼ 171 12 (7.0%) <.001 29 (17%) <.001 52 (25%) .297
No, N ¼ 607 5 (0.8%) 43 (7%) 158 (26%)
Renal dysfunction
Yes, N ¼ 53 2 (3.8%) .324 5 (9.4%) .963 15 (7%)
No, N ¼ 725 15 (2.1%) 67(9.2%) 195 (26.8%) .263
Diabetes mellitus
Yes, N ¼ 120 4 (3.3%) .316 14 (15%) .321 27 (13%) .274
No, N ¼ 658 13 (2.0%) 58(8.2%) 183 (27.8%)
Neoadjuvant therapy
Yes, N ¼ 109 2 (1.8%) 1.00 7 (6.4%) .356 25 (12%) .463
No, N ¼ 669 15 (2.2%) 65 (9.7%) 185 (27.6%)
Type of pulmonary resection .011
Pneumonectomy, N ¼ 15 2 (13%) 5 (33.3%) .004 13 (87%) <.001
Lobectomy/Bilobectomy/sleeve, N ¼ 499 9 (1.9%) 42 (8.4%) 139 (28%)
Sublobar, N ¼ 264 6 (2.3%) 24 (9.0%) 58 (21%)
Highest education*
Twelfth grade or less, N ¼ 297 8 (2.7%) .550 39 (13%) .051 78 (37%) .197
Some college or college graduate, N ¼ 281 2 (1.4%) 20 (7%) 65 (31%)
Graduate degree, N ¼ 120 3 (2.5%) 13 (11%) 67 (32%)
Annual household income* .588
<$25,000, N ¼ 346 8 (2.3%) .189 29 (9%) 122 (58%) <.001
$25,001–$50,000, N ¼ 327 5 (1.5%) 35 (11%) 71 (34%)
>$50,000, N ¼ 85 4 (4.7%) 8 (9.4%) 17 (8%)
No.of persons in household (includes patient)
1–2, N ¼ 349 6 (1.7%) .470 43 (12.3%) .011 110 (52%) .013
 3, N ¼ 429 11 (2.6%) 29 (6.8%) 100 (48%)
N, Number of patients; FEV1%, forced expiratory volume in 1 second; DLCO%, percent diffusion capacity of the lung for carbon dioxide. *Data not available for all patients.
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TABLE 5. The variables in this table remained significant predictors
after multivariate analysis of operative mortality, major morbidity
and overall morbidity
Variables Odds ratio (95% CI)
Operative mortality
Smoking history>20 patient-years and
current smoker
2.1 (1.08–4.53)
Coronary artery disease 1.8 (1.17–8.51)
Major morbidity
All critical benchmarks achieved 2.2 (1.53–3.55)
Coronary artery disease 2.4 (1.68–3.53)
Smoking history>20 patient-years and
current smoker
1.9 (1.80–3.74)
Age  67 years 1.5 (1.13–2.72)
Overall morbidity
All critical benchmarks achieved 1.7 (1.14–2.70)
Weighted score<117 2.1 (1.35–3.44)
Coronary artery disease 2.9 (2.5–4.17)
Type of pulmonary resection 1.3 (1.14–2.85)
Age  67 years 1.8 (1.21–2.70)
CI, Confidence interval.
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charge by postoperative day 4 or sooner.’’ This too is often
a surrogate for patients who have some sort of postoperative
complications. For this reason we do not want to overstate
the importance of benchmark delivery on our findings be-
cause of the subjectively selected benchmarks, the weighted
score, or the fact it examined one specialized practice. Yet,
benchmark delivery did reduce perioperative morbidity and
produce a trend toward lower mortality.
Inasmuch as we wanted to determine whether the bench-
marks or pay for performance concept could be teased out
as a predictor of morbidity, we performed a weighted analy-
sis.We assigned scores from1 to 5 for the importance of each
benchmark based on its impact for outcomes. We only con-
sidered benchmarks that all patients were eligible to receive
and benchmarks that only dealt with quality of care issues.
Although this weighted score was statistically related to
overall morbidity andmajor morbidity, it toowas not associ-
ated with operative mortality. Finally, we found that the lack
of delivery of all 10 of the critical benchmarks was associ-
ated with increased major morbidity and overall morbidity.
The strengths of this study were the large cohort over
a relatively short temporal period, minimization of variabil-
ity by having only 1 surgeon and 1 surgical team, and the
availability of actual socioeconomic data (rather than using
surrogate markers that are often seen in large registries such
as Surveillance Epidemiology and End Results or Medicare
databases). The limitations are that the benchmarks were
subjectively selected and that this scoring system has not
yet been validated.
In conclusion, in this single-center study we found that
benchmarks that represent both high quality of care and
high patient satisfaction for thosewith NSCLC can be deliv-30 The Journal of Thoracic and Cardiovascular Surgeered. This is especially true for those that are concerned
with care just before surgery and those benchmarks that
are carried out intraoperatively. The vast majority of
patients can receive all of the critical benchmarks. This re-
duces major morbidity. The delivery of all 53 of the subjec-
tively chosen metrics of quality that we selected also
reduced perioperative morbidity. The delivery of the bench-
mark did lead toward a trend of lower operative mortality,
but only patient characteristics such as smoking history
and coronary artery disease were predictors on multivariate
analysis. Importantly, socioeconomic factors that are too
infrequently considered significant also were predictors of
poor patient outcomes. We found that having more than 1
other person in the household was a univariate predictor
of both increased overall and major morbidity. Having an
annual household income of less than $25,000 was also
a univariate predictor of increased overall morbidity. Given
these findings, not only is the ‘‘quality of the health care
provider’’ important but the ‘‘quality of the patient’’ should
not be underestimated. Carefully designed and analyzed
multi-institutional studies are needed to better understand
these complicated and multifactorial issues. The concepts
of benchmarks, quality of care, and pay for performance
in general thoracic surgery, all of which are part of our
future, require further study.
References
1. Institute of Medicine. Crossing the quality chasm: a new health system for the
21st century. Washington (DC): National Academies Press; 2001.
2. Baker G, Carter B. Introduction to case studies in health plan pay-for-perfor-
mance. Washington (DC): Atlantic Information Services; 2004.
3. Hillman AL, Ripley K, Goldfarb N, Nuamah I, Weiner J, Lusk E. Physician
financial incentives and feedback: failure to increase cancer screening in Medic-
aid managed care. Am J Public Health. 1998;88:1699-701.
4. Grady KE, Lemkau JP, Lee NR, Caddell C. Enhancing mammography referral in
primary care. Prev Med. 1997;26:791-800.
5. Glickman SW, Ou FS, DeLong ER, Roe MT, Lytle BL, Mulgund J, et al. Pay for
performance, quality of care, and outcomes in acute myocardial infarction.
JAMA. 2007;297:2373-80.
6. Nahra TA, Reiter KL, Hirth RA, Shermer JE, Wheeler JR. Cost-effectiveness
of hospital pay-for-performance incentives. Med Care Res Rev. 2006;63:
49S-72.
7. Gilmore AS, Zhao Y, Kang N, Ryskina KL, Legorreta AP, Taira DA, et al. Patient
outcomes and evidence-based medicine in a preferred provider organization
setting: a six-year evaluation of a physician pay-for-performance program.
Health Serv Res. 2007;42:2140-59.
8. Curtin K, Beckman H, Pankow G, Milillo Y, Green RA. Return on investiment in
pay for performance: a diabetes case study. J Healthc Manag. 2006;51:365-76.
9. Cassivi SD, Allen MS, Vanderwaerdt GD, Ewoldt LL, Cordes ME, Wigle DA,
et al. Patient-centered quality indicators for pulmonary resection. Ann Thorac
Surg. 2008;86:927-32.
10. Martin-Ucar AE, Medouye A, Deacon SE, Muhibullah N, Lau K, Bennett J, et al.
Systematic evaluation of quality of care provided to patients undergoing pulmo-
nary surgery helps to identify areas for improvement. Inter Cardiovasc Thorac
Surg. 2010;10:394-8.
11. Cerfolio RJ, Bryant AS, Maniscalco LM. A nondivided intercostal muscle flap
further reduces pain of thoracotomy: a prospective randomized trial. Ann Thorac
Surg. 2008;85:1901-6.
12. Cerfolio RJ, Bryant AS, Patel B, Bartolucci AA. Intercostal muscle flap reduces
the pain of thoracotomy: a prospective randomized trial. J Thorac Cardiovasc
Surg. 2005;130:987-93.
13. Cerfolio RJ, Price TN, Bryant AS, Sale Bass C, Bartolucci AA. Intracostal
sutures decrease the pain of thoracotomy. Ann Thorac Surg. 2003;76:407-11.ry c January 2011
Cerfolio and Bryant General Thoracic Surgery
G
T
S14. Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esopha-
geal ultrasound fine-needle aspiration in patients with non–small cell lung cancer
who are clinically N2 negative: a prospective study. Chest. 2006;130:1791-5.
15. Cerfolio RJ, Bryant AS, Eloubeidi MA, Minnich DJ, Harbour KC,
Dransfield MT. The true false negative rates of esophageal and endobronchial
ultrasound in the staging of mediastinal lymph nodes in patients with non–small
cell lung cancer. Ann Thorac Surg. 2010;90:427-34.
16. US Department of Health and Human Services. https://www.cms.gov/pqri/ (last
accessed 9/8/10)
17. Society of Thoracic Surgeons Web site, http://www.sts.org/documents/pdf/ndb/
1_-_Sample_Report_GT_Overview_-_88888.pdf (p. vii). (last accessed 6/7/10).
18. Centers for Medicare & Medicaid Services http://www.cms.gov/PQRI/
15_MeasuresCodes.asp#TopOfPage (last accessed 9/7/10).
19. Copeland GP, Jones D,Walters M. POSSUM: a scoring system for surgical audit.
Br J Surg. 1991;78:355-60.
20. WhiteleyMS, Prytherch DR, Higgins B,Weaver PC, ProutWG. An evaluation of
the POSSUM surgical scoring system. Br J Surg. 1996;83:812-5.
21. Borja-Cacho D, Parsons HM, Habermann EB, Rothenberger DA,
Henderson WG, Al-Refaie WB. Assessment of ACS NSQIP’s predictive ability
for adverse events after major cancer surgery. Ann Surg Oncol. 2010;17:2274-82.Discussion
Dr John R. Handy (Portland, Ore). I thank the Association for
the invitation to make some comments and to pose some questions.
Dr Cerfolio, your prodigious work effort always impresses a room
full of people who dedicate their lives to prodigious work efforts,
and this particular project is a tour de force in database detail and
the actual gathering of data. I do not know how you and Dr Bryant
actually pulled it off. It is the source of a fascinatingmystery tome.
When I look at these types of efforts, I find it instructive to view
them through the lens of the Donabedian formula for health care
quality as defined by the structure in which the care is rendered,
the processes of the care, and the outcomes. There is often a blur-
ring of the terminology when discussing quality or its components.
Finally, I wonder whether you have not undersold your conclu-
sions in that one very viable conclusion that you could have from
your same data is that optimal care decreased morbidity. This is
important because morbidity not only has human suffering but
also has cost implications and, frankly, in high-quality programs,
we probably have more opportunity for decreasing morbidity
than mortality.
I have 3 questions, the first of which you already mentioned. My
first question concerns the identification of your benchmarks, espe-
cially your critical versus your noncritical benchmarks, especially
vis-a-vis things for which there are very few data, such as accom-
plishing a lobectomy in less than an hour and 40minutes or a blood
loss of less than 100mL. You are in a lonely position in this nascent
field and your efforts are to be commended, but this is not a field
devoid of information. The National Surgery Quality Improvement
Program (NSQUIP), the POSSEM score (Physiologic and Opera-
tive Severity Score for Enumeration of Morbidity and Mortality),
and the Mayo Clinic, for example, in 2008 Annals of Thoracic Sur-
gery using 9 senior clinicians, including nonsurgeons such as phy-
sician’s assistants and nurses, came up with patient-centered
quality indicators for pulmonary resection. Finally, last year in
the European Journal of Cardio-Thoracic Surgery the Glenfield
Hospital group published a similar-type effort. So can you defend
your selection of these particular 55 criteria?
Dr Cerfolio. First, thank you for your kind comments. It is
a great question and the truth is that I really cannot defend them.The Journal of Thoracic and CThose were things that we believed as a team. As you said, there is
some literature out there, but not very specific nor validated bench-
marks, particularly this set of patients that we have. That is why I
list this as one of the weaknesses of the study: our benchmarks are
not validated either.
Dr Handy. Second, can we use your practice to draw conclu-
sions for the greater thoracic surgery community at large? Your
program leverages the widely described benefits for improving
outcomes, including high clinical volume, multidisciplinary
care, and specialized care. Those are really not debatable. If you
do the math, you are doing over 250 pulmonary resections for
cure annually. Boffa’s report of the general thoracic surgery data-
base in the 2008 Journal of Thoracic and Cardiovascular Surgery
is contributed to only by board-certified general thoracic surgeons.
We are performing a median of 31 pulmonary lobectomies a year.
So you are doing good things, but you are also not doing some
things that had been shown to be of benefit. In February 2010,
our 3 major journals, the Journal of Thoracic and Cardiovascular
Surgery, the Annals of Thoracic Surgery, and the European Jour-
nal of Cardio-Thoracic Surgery, showed that video-assisted
(VATS) lobectomy had less perioperative morbidity, had improved
6-month functional outcomes, and also had the same oncologic
benefit at 5 years, so VATS lobectomy is a hard thing not to
perform when you are talking about quality of care.
DrCerfolio. I agree and those are excellent points. After going to
meeting after meeting, I would be dishonest scientifically if I did not
say that I now believe that minimally invasive lobectomy, which can
be done with VATS, may decrease morbidity. However, it is the im-
proved 5-year survival of several reports that really gotme interested
in revisiting the concept of VATS, and after doing several more I
started doing robotic lobectomies.We have done 46 completely por-
tal robotic lobectomies now. It has changed my life in someway for
the worse—home later—but it has been better for my patients in
many ways. I have seen decreased morbidity doing minimally inva-
sive robotic lobectomy. I am still not a big fan ofVATS formany rea-
sons. I still see a lot of pain from camera torquing on the intercostal
nerve, probably because I have medical students most commonly
driving my camera. I run several rooms and have a different medical
student in each room who runs the camera, and as soon as they get
good they are gone 2 weeks later. With robotic lobectomy, the sur-
geon drives the camera. With our technique, the surgeon provides
the retraction using the robotic fourth arm, and the visibility, the
lymphnodedissection, and thevessel andN1dissection are unequiv-
ocally easier to dowith the robot than with VATS. It has been some-
thing that we are studying. I am a proponent of it, but I think we need
to carefully study the increased cost and the time. However, we have
seen decreased morbidity with it. It is a good point.
Dr Handy. Third, you accomplished your critical benchmarks
and decreased morbidity. What exactly is the linkage for that?
DrCerfolio.That is another great question. The real question is,
are the critical benchmarks nothing more than surrogates for
patients doing well, as I tried to allude to in the presentation? If
one benchmark is that the patients go home in 4 days, and then if
they do not hit that benchmark and it is critical, then obviously
therewas a problem. In away they are surrogates for patients doing
well, but I think there is a little bit more to it than just that. As you
say, this is an extremely complicated studywhere there are somuch
data that we are not sure if we have completely analyzed all of it allardiovascular Surgery c Volume 141, Number 1 31
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chewing this out a little bit to help us make it better.
Dr Richard Whyte (Stanford, Calif). I applaud you on a great
presentation and for your continued self-examination. I have
a comment and a couple of questions.
First of all, I think that your final statement that ‘‘pay for perfor-
mance is unsupported’’ is carefully chosen wording and, perhaps,
better than calling it ‘‘unsupportable.’’ I think that was intentional.
Well done.
Dr Cerfolio. Right.
DrWhyte. I think part of that may be because quality is not just
short-term mortality, but also long-term mortality, length of stay,
cost, and, as Scott Millikan pointed out so poignantly, relationships
with the patient and his or her family. When you focus on just one
area of quality, short-term mortality, I think that you miss some of
the aspects of quality that are so important.
I have a couple of questions. First, maybe I misunderstood
things, but in your presentation you pointed out that missing major
benchmarks did not affect mortality.
Dr Cerfolio. It did not. The lack of delivery of the 10 critical
benchmarks did not negatively affect operative mortality, but it
was associated with increased major morbidity.
Dr Whyte. Okay, I was not sure. In the abstract it seemed to be
different.
Dr Cerfolio. Things have changed since the abstract was sub-
mitted because we have done so many more statistical analyses.
I cannot tell you what a pain in the neck this one has been, but
we have done a million analyses since the abstract, so some mes-
sages have changed for sure.
Dr Whyte. Last, the educational component to this: you said
97% of the time you made all your intraoperative benchmarks.
Now one of those on your list was the surgeon performing the
skin incision.
Dr Cerfolio. Yes.
Dr Whyte. How do you teach the residents, particularly when
you have chief residents, if 98% of the time you are doing the
operation from skin to skin?
Dr Cerfolio. You have misinterpreted me making the incision
versus me doing the whole case. I make the skin incision and
then I give them the Bovie instrument and have them go from there.
However, the point is I am there the entire time. I tell the patients
who come tome that I am there. I make the skin incision. I am there
for all the critical parts and really for the entire procedure, and I
hold my word to the patients. But then I usually give the resident
or the fellow the Bovie instrument as soon as I make the incision.
Dr Whyte. Interesting distinction.
Dr Cerfolio. No, I do. I make the skin incision and I am there
when the skin is closed; I am there essentially the whole time.
I may leave to do a rigid bronchoscopic procedure or a mediastino-
scopy in the middle of a robotic lobe, and I tell them that; we leave
a little extra time and use an hour and 40 minutes in there because
I leave sometimes, but I am there when the operating is being done
and for the opening and closing.
Dr Whyte. So are you serious that a major quality index is that
you, personally, make a skin incision and then hand the Bovie in-
strument to someone else to do a lot of the operation?
Dr Cerfolio. Yes. I am aware of some places where there is
some ghost surgery going on, and I know at least when I was doing32 The Journal of Thoracic and Cardiovascular Surgeit, mistakes resulting from inexperience were made. I think if you
have a senior person there taking a resident or a fellow through the
procedure, it is safer than the younger resident by himself. If the
resident or fellow does it by himself or herself, depending on the
level of experience, I think the quality of the product goes down.
Dr Whyte. I would agree with that. Thank you.
Dr Paul Schipper (Portland, Ore). I had a comment and a ques-
tion. Now I have 2 questions.
When I read through your critical benchmarks in the published
abstract, I noticed all of them with one exception were things that
happened to you—as you said, surrogates for problems that oc-
curred. The patient goes to the ICU, bleeding, transfusion. The
only one that you could affect was whether or not they got pulmo-
nary rehabilitation before the operation. In the new revised list of
critical benchmarks, which of them can we do or affect and expect
a better outcome?
Dr Cerfolio. It really gets tricky because if you talk to Ayesha
Bryant, my partner and statistician, we can only allow patients who
were eligible for a benchmark to be considered whether they got it.
In other words, smoking cessation was a benchmark, but if the pa-
tient did not smoke, he or she was not eligible to get that particular
benchmark. It gets very tricky when you look at what benchmarks
you have delivered, because you do not want to penalize yourself
for not delivering a benchmark that a particular patient was not
even eligible for. We selected cardiopulmonary rehabilitation for
selected patients, so the majority of patients who were supposed
to get it were supposed to get it for a month. However, that was
the lowest benchmark we delivered, because too often the patient
is at home watching ESPN using the television remote control sit-
ting in a recliner. He or she was not really doing the cardiopulmo-
nary rehabilitation. Some of these things go on to the patient and
patient factors.
Dr Schipper. This study shows your attention to detail and your
ability to be self-critical, but I disagree somewhat with your
conclusion about pay for performance.
Dr Cerfolio. It is easy for us to be self-critical, but go ahead.
Dr Schipper. The nationwide mortality for lobectomy is some-
where between 5% and 7%, and yours is about half of that. What
this study really represents is Team Rob Cerfolio doing all the
things that you think you ought to do versus Team Rob Cerfolio
when you stumble. Even when you stumble your outcome is better
than that national average, so why not advocate pay for perfor-
mance? You would probably get paid.
Dr Cerfolio.Well, I appreciate your saying that, but I am going
to challenge you on that.We all know that there are many series out
there, some from those in this audience, that show operative mor-
tality less than 2%. I have never been able to achieve that and I
have been doing this for 14 years. I am very disappointed about
that. There are a lot of very good surgeons in this room who
have big series with mortalities of 1.8% and 1.7%. I think with
our robotic lobectomies we may get there.
Dr Schipper. But these are from the STS database and series
out of Memorial Sloan Kettering. They are the cream of the
crop, not the true national average.
Dr Cerfolio. You are right, but I think the minimally invasive
technique, as much as I have been a very loud voice against it,
may be able to decrease some of the mortality and the morbidity.
Some of it is patient selection, but some of it is some of these otherry c January 2011
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halfway to 100 robotic lobectomies, and we will see where we
are. So far, we have had no mortalities and the morbidity has
been less.
Dr Scott Rankin (Nashville, Tenn). Congratulations on a very
interesting approach. I would like to make one small methodologic
comment about this paper and also Dr Grossi’s paper. A principle
of biostatistics is that 10 events should be available for every vari-
able tested in a multivariable analysis. Without that, we have the
potential for over-fitting. I am concerned that with the small num-
ber of events, testing so many variables represents over-fitting in
the multivariable analysis.
Dr Cerfolio. That is a very good point. Dr Bryant and I have
talked about that very fact as well. You asked whether it is a mys-Patient Demograph
Survey Number ______________________ D
What state do you live in? ______________ W
Have you ever smoked tobacco?     Yes No
If yes, what kind of cigarette did you smoke most o
How many packs per day did you smoke?  ______
When was your last cigarette?  _______________
What is your job (if retired, what was your job before retire
How many other people live in your home (not counting yo
How long ago did your primary doctor refer you to see Dr. 
How many times each year do you see your primary care 
ob/gyn, internest)? ______________
What is the highest level of education that you completed?
Less than 8th grade Some high schoo
Trade school/technical Some college wo
Some graduate work Graduate degree
What is your household income per year (average of the la
Less than $15,000/year $15,001-25,000
$50,001-75,000 $75,001-100,000
APPENDIX 1. Survey giv
The Journal of Thoracic and Ctery how we do these. Well, it is not a mystery. We have constant
communication. Many times she hates me and sometimes I get
tired of her because we are always talking about our studies every
single day.
I dowant to make 1 last comment. I was talking about quality of
care and patient satisfaction. We heard earlier today from our pres-
ident that ‘‘hope is the currency of the waiting room.’’ I think he is
exactly right. We need more benchmarks that look at patient and
family satisfaction, not just surgical intraoperative benchmarks.
That is why I have so many of these in this paper. We may even
need more, because that is really how we are measured, not just
our outcomes but what the family perceives of the product we
have delivered, even when the end result is not the one we were
praying for preoperatively.ic Survey
ate:__________________________
hat is your zip code? ____________
ften?  Menthylated    Non-menthylated  Other           
How many years have/did you smoke? ______  
____
ment)?
urself)? __________
Cerfolio? ___________________
physician (for example: your family doctor, your 
  
l Graduated high school
rk Graduated college with degree
 (MS) Graduate degree (doctorate)
st 10 years)?
$25,001-50,000
$100,001 or more
en in clinic to patients
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